/

ANIX

Anixa Biosciences, Inc.Open

2.74−0.11 −3.70%USD

NasdaqCM · as of Oct 13, 12:40 ET · 15m delay

Open

2.84

Prev close

2.84

Day range

2.722.84

52-week range

2.325.46

Volume

72.30K0.24×

Mkt cap

95.08M

P/E ttm

—

Fwd P/E

-8.82

EPS ttm

-0.3200

Div yield

0.00%

Earnings

Sep 9, 2026

From 52w high

−49.91%

Price Chart

Yahoo Finance · delayed

ANIXOct 13, 2026O 2.84H 2.84L 2.72C 2.73−0.11 (−3.70%)Vol 72.30K

SMA 503.10
SMA 2002.99

1Y change −36.84% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ANIX Anixa Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.44%
1 month: −0.91%
3 months: −14.26%
6 months: −5.03%
Year to date: −12.34%
1 year: −39.49%

Valuation & ownership

Market cap: 95.08M
Enterprise value: 83.77M
P/E (ttm): —
Forward P/E: -8.82
PEG ratio: -0.11
Price / book: 6.54
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.3200
EPS (forward): -0.3100
Beta (5y monthly): 0.48
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 34.76M
Float: 32.81M
Short % of float: 4.10%
Short ratio (days): 3.58
Held by insiders: 5.62%
Held by institutions: 13.85%
Avg volume (3m): 302.26K
50-day average: 3.11
200-day average: 2.99
52-week change: −39.49%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 40.0
vs 50-day SMA: −11.65%
vs 200-day SMA: −8.46%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.56%
Realised vol (20d, ann.): 49.2%
From 52-week high: −49.91%
From 52-week low: +17.89%

ANR

Analyst Consensus

4 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.75

+256.49% implied

Low 6.00Median 9.50High 14.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0

Buy / hold / sell counts

DES

About Anixa Biosciences, Inc.

Yahoo Finance profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 4
Headquarters: San Jose, CA, United States
Website: anixa.com
Officers: Dr. Amit Kumar Ph.D. CEO, Chairman & Co-Chair of CBAB
Mr. Michael J. Catelani CPA, MBA President, COO, CFO & Corporate Secretary
Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board

SEAS

Seasonality · ANIX

2007–2026 · monthly returns

Strongest month Sep +22.40%Weakest month Dec −7.96%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.6	-2.0	-13.4	16.3	-10.0	3.7	22.1	-2.0	-12.5	-6.7			−12.3%
2025	25.0	8.6	-9.2	-2.4	-7.9	28.4	-7.3	-2.3	10.4	25.2	11.1	-32.0	+34.5%
2024	17.0	-22.9	-10.9	-4.8	-18.2	-9.1	50.2	0.6	-5.7	11.1	-5.7	-29.7	−40.2%
2023	2.8	1.1	-2.7	-5.1	-25.0	4.6	12.2	2.2	-10.9	-3.4	5.7	16.2	−8.7%
2022	10.4	-15.2	-1.4	18.6	10.5	-14.8	24.2	9.7	18.0	13.8	-10.0	-15.7	+43.1%
2021	18.9	38.6	-7.5	4.3	-18.6	-2.3	13.9	26.7	-14.8	0.0	-23.7	-18.4	−3.3%
2020	8.2	-15.8	-46.8	18.9	20.6	34.2	-9.2	-28.8	22.7	-15.2	28.2	16.3	−6.4%
2019	30.2	-1.4	-10.7	-8.0	0.2	-12.9	29.2	-15.4	0.8	-3.3	-1.0	-14.4	−16.8%
2018	58.1	-11.8	16.7	-2.9	-5.6	-13.9	8.6	15.8	21.8	-12.7	-3.2	0.5	+66.9%
2017	-9.3	-19.4	-24.1	-35.0	-56.9	36.9	-31.3	-15.2	292.5	-22.1	22.0	-5.6	−56.3%
2016	-2.3	-21.1	29.7	-6.3	14.9	-3.1	1.3	27.7	-4.2	63.2	-10.2	-5.3	+79.4%
2015	0.0	-9.1	30.0	-7.7	8.3	23.1	22.2	-14.3	13.4	-21.7	-24.5	7.1	+9.5%
2014	110.5	-25.0	0.0	13.3	-11.8	0.0	-13.3	3.8	-11.1	-16.7	-15.0	-35.3	−42.1%
2013	33.3	-12.5	-4.8	15.0	43.5	-15.2	-21.4	0.0	-13.6	5.3	5.0	-9.5	+5.6%
2012	0.0	63.6	11.1	-15.0	-29.4	0.0	0.0	0.0	100.0	8.3	-23.1	-10.0	+63.6%
2011	-19.0	5.9	0.0	27.8	73.9	-10.0	-38.9	-13.6	-15.8	0.0	-18.8	-15.4	−47.6%
2010	-18.8	-5.8	-20.4	0.0	-17.9	-9.4	-17.2	-4.2	-8.7	4.8	13.6	-16.0	−67.2%
2009	-27.9	-12.9	-3.7	11.5	-3.4	39.3	-10.3	60.0	51.8	-30.6	16.9	-7.2	+48.8%
2008	-17.9	-16.0	-13.0	16.1	-9.9	-17.6	0.0	-6.7	-12.9	-21.3	-29.2	26.5	−70.3%
2007	-5.2	-8.7	-13.1	-11.0	-4.6	-6.5	-6.9	63.0	-8.0	11.1	66.7	-3.3	+49.5%

INSD

Insider Activity · ANIX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 29, 2026	Catelani Michael JOfficer	Purchase at price 2.84 per share.	5.5K	$15.62K
Sep 23, 2026	Kumar AmitChief Executive Officer	Purchase at price 2.78 per share.	7K	$19.46K
Sep 23, 2026	Baskies Arnold MDirector	Purchase at price 2.76 per share.	5K	$13.80K
Sep 9, 2026	Titterton Lewis H JrDirector	Purchase at price 2.73 per share.	10K	$27.30K
Sep 9, 2026	Kumar AmitChief Executive Officer	Purchase at price 2.76 per share.	5K	$13.80K
Sep 9, 2026	Kumar AmitChief Executive Officer	Purchase at price 2.75 per share.	3K	$8.25K
Jul 30, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.47 per share.	5K	$17.35K
Jul 26, 2026	Baskies Arnold MDirector	Conversion of Exercise of derivative security at price 3.13 per share.	6K	$18.78K
Jul 26, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.37 per share.	3.2K	$10.74K
Jul 26, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.44 per share.	5K	$17.20K
Jul 23, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.73 per share.	3K	$11.19K
Jul 19, 2026	Titterton Lewis H JrDirector	Purchase at price 3.47 per share.	12K	$41.64K
Jul 19, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.46 per share.	5K	$17.30K
Jul 14, 2026	Titterton Lewis H JrDirector	Purchase at price 3.28 per share.	2.8K	$9.17K
Jul 9, 2026	Kumar AmitChief Executive Officer	Purchase at price 3.04 per share.	5K	$15.20K
Jun 15, 2026	Titterton Lewis H JrDirector	Purchase at price 2.64 per share.	2.8K	$7.49K
Jun 11, 2026	Kumar AmitChief Executive Officer	Purchase at price 2.50 per share.	21K	$52.50K
Jan 27, 2026	Baskies Arnold MDirector	Purchase at price 3.04 per share.	10K	$30.40K
Dec 14, 2025	Titterton Lewis H JrDirector	Conversion of Exercise of derivative security at price 2.92 per share.	16K	$46.72K
Oct 29, 2025	Kumar AmitChief Executive Officer	Conversion of Exercise of derivative security at price 2.92 per share.	200K	$584.00K

13F

Investors Holding ANIX

latest 13F filings of 29 followed managers

Investors holding ANIX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$166.2K	0.00%	59.37K	−2.9%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ANIX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ANIX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Anixa Biosciences, Inc.

Seasonality · ANIX

Insider Activity · ANIX

Congress Trades · ANIX

Investors Holding ANIX

Investors Holding ANIX

Congress Trades · ANIX

Insider Activity · ANIX

Seasonality · ANIX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Anixa Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News